About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT02832570

Sildenafil Efficacy Study on Time Walk From Peripheral Arterial Desease Patients (Stade II) With Arterial Claudication

Efffect of a single dose oral intake of sildenafil Or placebo on the walking capacity on treadmill of PAD patients with claudication

Lead sponsor: University Hospital, Angers•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University Hospital, Angers

Sildenafil 100mg or Placebo Oral intake 2 hours before the treadmill test Safety and security control throughout the period of drug efficacy (approx 4 hours) Evaluation of maximal walking distance for a constant load treadmill test (3.2 kml/h 10% slope)

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patient with peripheral arterial desease stade II
•Patient with vascular claudication for at least 3 months
•Patient able to perform a treadmill walking test with time to walk \< 5min

Exclusion Criteria

•Patient suffering from ischemia
•Previous angina or myocardial
•Patient treated with nitrates drugs
•Patient with severe renal insufficiency
•Patient with severe hepatic insufficiency
•Patient with hypotension

Related studies

VITUS Post-Market Registry

NCT06832631 · Peripheral Arterial Disease, Peripheral Arterial Occlusive Disease

RECRUITINGEARLY Phase 1

Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)

NCT06204237 · Peripheral Arterial Occlusive Disease, Critical Limb Ischemia

RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients

NCT05961943 · Peripheral Arterial Disease, Sedentary Behavior, and more

The SIR-POBA Bypass Trial

NCT06056193 · Peripheral Arterial Occlusive Disease, Bypass Complication, and more

Not Yet RecruitingNA

Wearable Devices Assist in the Detection, Screening, and Management of Major Diseases in Middle-aged and Elderly Populations

NCT06980064 · Coronary Stenosis, Cerebral Arterial Diseases, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 29, 2022Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment14

Start dateNov 2016

Last updatedJul 29, 2022

Condition

Peripheral Arterial Occlusive Disease

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 29, 2022Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions